This inventor holds 21 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Glaxo Group Limited, Glaxosmithkline LLC, Smithkline Beecham Corporation. Active years: 2006-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ware, GB (2006)
- Stevenage, GB (2006 - 2020)
Company Filing History:
15 out of 1,170 
2 out of 358 
2 out of 2,198 
Years Active: 2006-2020
Areas of Expertise:
Title: Jonathan Henry Ellis: Innovator in Therapeutic Antibodies
Introduction: Jonathan Henry Ellis, based in Stevenage, GB, is a prolific inventor with a total of 21 patents to his name. His contributions primarily focus on advancements in therapeutic treatments, particularly through the development of humanized antibodies.
Latest Patents: Among his latest inventions is a notable patent titled "Method of treatment with humanized anti-IL-18 antibodies." This patent discloses innovative humanized anti-IL-18 antibodies, detailing methods of manufacture and therapeutic application. The invention includes sophisticated screening methods, such as surface plasmon resonance, to identify antibodies with promising therapeutic potential. Additionally, he holds another significant patent with a similar title, reinforcing his commitment to enhancing treatment strategies using humanized anti-IL-18 antibodies.
Career Highlights: Throughout his career, Jonathan Henry Ellis has made substantial contributions to the pharmaceutical field. He has worked with esteemed companies, including Glaxo Group Limited and GlaxoSmithKline LLC, where he applied his expertise in developing cutting-edge therapeutic solutions.
Collaborations: Jonathan has collaborated with esteemed colleagues, such as Volker Germaschewski and Paul Andrew Hamblin. These collaborations have fostered innovative approaches in the field of antibody research and development, reflecting a strong network of expertise.
Conclusion: Jonathan Henry Ellis stands out as a significant figure in the realm of therapeutic innovation. His work on humanized anti-IL-18 antibodies not only showcases his inventiveness but also highlights the potential for improved treatment methods in the medical field. With a strong patent portfolio and influential collaborations, he continues to contribute to advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile